Age/Sex Site type TNM Hist. Nod. Ope Hepa. Chemtherapy Prog.(M)
60/M LD 3 T4bN2 pap 2 D. D2 Colon + CDDP+5-FU*, PR 19D. H.,bone
66/M M 2 T3N2 por1 3 D. D2 + CDDP+5-FU/5-FU 43D. H.
63/M UE 3 T4aN1 por2 1 T+SD2 - 5-FU, PD 13D. H.
54/M UE 2 T4bN0 tub1 1 T. D3 + MMC,5-FU+CDDP/UFT, S-1 32D. H.,L.
61/M L 2 T4aN1 tub1 2 D. D2 - CDDP/S-1,5’-DFUR, SD 32D.H.N.
75/M LMU 3 T4bN2 tub1 ≥ 4 D. D1 - CDDP/5’-DFUR,PSK,CR 67A.
72/M LMU 5 T4aN3b tub1 ≥ 4 T. D1 - CDDP/S-1**, PR 44D. H.
67/M UE 2 T4aN2 tub1 3 T, D1 - CDDP/S-1, PR 33DN,bone
66/M ML 2 T4aN3a tub1 ≥ 4 D.D1 - CDDP/S-1, SD 26D. H.
64/M U 1 T4aN3a M1LYM por1 ≥ 4 T+S,D1 - CDDP/S-1, SD 12D. H.
56/M LD 3 T4aN3b M1LYM tub1 ≥ 4 D. D1 - CDDP/S-1, SD 8D. H.
77/F LMU 3 T4aN3b P1M1LY tub2 ≥ 4 D. D0 - CDDP/S-1, PR CDDP/CPT-11 19D.
71/M U 3 T4aN3b por1 2 T+S,D2 - CDDP/S-1, SD 10D. H.
65/M U 2 T4aN2 tub2 ≥ 4 T, D2 - CDDP/S-1,PR, S-1+TXL, S-1+CDDP+TXL 19D. L.
65/M UM 3 T4aN3a por1 2 T, D1 - pre.S-1+CDDP(4 c. PD) CDDP/S-1 PD 6D. N.,H.
65/M LM 3 T4aN3b por1 ≥ 4 D,D2 - pre.S-1+TXL(5c. PR) CDDP+MMC/S-1  PD 3D. N.,H.
68/M LD 1 T4aN0 tub2 2 D, D2 - CDDP/S-1,5’-DFUR, PR 38D.
M male, F female, L lower third portion, M middle third portion, U upper third portion, T depth of tumor invasion, N lymph node metastasis, M distant metastasis, M1LYM distant lymph node metastasis, P peritoneal metastasis, Hist histology, pap papillary adenocarcinoma, por1 poorly differentiated adenocarcinoma solid type, por2 poorly differentiated adenocarcinoma non-solid type, tub1 tubular adeno carcinoma well-differentiated, tub2 tubular adenocarcinoma moderately differentiated, Nod the number of metastatic nodule, Ope operation, D distal gastrectomy, T total gastrectomy, S splenectomy, Hepa hepatectomy, pre preoperative chemotherapy, c cycle, Prog prognosis, M month, D dead, A alive, H recurrence in the liver, L recurrence in the lung, N recurrence in the lymph node, *patient underwent hepatectomy after HAI, **patient underwent coagulation after surgery
Table 4: Cases who underwent hepatic arterial infusion (HAI).